Sanjeev Khindri, the Chief Development Officer at Liquidia Corp (NASDAQ:LQDA), has executed a transaction involving the sale of company equity. On July 13, 2026, Khindri sold a total of $84,740 worth of common stock. The transaction involved the disposition of 1,185 shares, which were sold at prices ranging from $71.39 to $71.52 per share.
According to the filing, these sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan. Khindri adopted this specific plan on March 9, 2026. The filing indicates that the shares were sold to cover tax obligations associated with the settlement of restricted stock units (RSUs). These RSUs were initially granted to Khindri on February 10, 2025.
Following the completion of these transactions, Khindri directly holds 65,947 shares of Liquidia Corp common stock. This total includes 25,432 unvested RSUs from the February 10, 2025 grant and 34,274 RSUs granted on January 16, 2026. None of these remaining RSUs had vested as of the filing date.
The insider activity occurs against a backdrop of significant price movement for Liquidia shares. The stock has surged 427% over the past year, though it has declined 3.75% in the past week. According to InvestingPro analysis, the stock appears undervalued at current levels and is featured on the platform’s Most Undervalued list. Investors seeking deeper insights can access 18 additional InvestingPro Tips and comprehensive analysis through the platform’s detailed Pro Research Report, available for LQDA and over 1,400 US equities.
In other recent news, Liquidia Corporation has been making headlines with several key developments. The company reported a successful launch of its drug Yutrepia, prompting BofA Securities to adjust its peak sales estimate from $1.7 billion to $2.2 billion. However, BofA downgraded Liquidia’s stock rating from Buy to Neutral due to a more balanced risk-reward profile after significant gains. Meanwhile, H.C. Wainwright increased its price target for Liquidia shares to $75, maintaining a Buy rating, influenced by a favorable Supreme Court ruling that could benefit Liquidia’s ongoing legal case.
Additionally, Raymond James reiterated a Strong Buy rating with a $68 price target, also citing the positive impact of the Supreme Court decision. Liquidia is set to join the S&P SmallCap 600 Index, effective before the opening of trading on June 22, 2026. This inclusion marks a significant milestone for the company, reflecting its market capitalization, liquidity, and profitability. These developments underscore the dynamic nature of Liquidia’s current market position and future prospects, as evaluated by various analyst firms.